- Home
- Posts
- 🍄 Trip Sheet: Compass Pathways (CMPS) eyes FDA approval path after positive Phase 3 psilocybin data
🍄 Trip Sheet: Compass Pathways (CMPS) eyes FDA approval path after positive Phase 3 psilocybin data
CPO Dr. Guy Levine tells The Fly the company is already designing a late-stage PTSD trial while preparing providers for COMP360 rollout.
Jul 10, 2025
One trade idea here could pay for your subscription 10x.
We don’t cover fluff. We cover ideas that move portfolios. Upgrade now, before you miss your next trade
Upgrade